Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 1216 for:    "Hodgkin lymphoma"

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03730363
Recruitment Status : Recruiting
First Posted : November 5, 2018
Last Update Posted : December 20, 2018
Sponsor:
Information provided by (Responsible Party):
Hayder Saeed, University of Kentucky

Brief Summary:

Primary Objective:

To evaluate dose limiting toxicity and to determine the recommended phase 2 dose (RP2D) of pentamidine in combination with salvage chemotherapy with ifosfamide, carboplatin and etoposide (ICE) on a 3-weeks schedule in relapsed/refractory classical Hodgkin lymphoma (cHL).

Secondary Objective:

  • To estimate the overall best treatment response at 5- and 16-weeks from study enrollment. Although the clinical benefit of these drugs in combination has not been established, offering this treatment may provide a therapeutic benefit. The patients will be carefully monitored for tumor response and symptom relief, in addition to safety and tolerability.
  • To estimate the duration of response to the proposed combined therapy.
  • To measure the protein of regenerating liver-3 (PRL-3) level of expression in patients at time of relapse.
  • To measure circulating biomarkers of response (soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC)) in serum samples collected throughout treatment and inhibition of (pSTAT, pAKT) in peripheral blood mononucleated cells (PBMC).

Exploratory Objective:

  • To measure cell-free messenger RNA (cfmRNA) in peripheral blood.
  • To measure cell-free DNA in peripheral blood

Condition or disease Intervention/treatment Phase
Hodgkin Lymphoma Refractory Hodgkin Lymphoma Drug: Pentamidine Phase 1

Detailed Description:

The primary objective of this Phase I study is to determine the maximum tolerated dose (MTD) of Pentamidine. A two-stage continual reassessment method (CRM) will be employed to determine dose escalation levels and the maximum tolerated dose (MTD) of Pentamidine.

Specifically, a modified two-stage CRM will be employed with 2 patients per cohort at each dose level. The trial starts with an escalation design from the lowest dose (2 mg/kg) with a traditional 2+2 dose escalation method. After occurrence of the first DLT, dose assignment will be determined by the CRM (2 patients/per cohort) using empirical model with restrictions to avoid dose-skipping and escalation immediately after a toxicity outcome.

A maximum of 12 patients will be enrolled into the trial during the escalation phase. Once the MTD is reached, an additional 4 patients will be treated at this dose. Thus, 6 or more patients will be treated at the MTD.

The target DLT rate is 33% and the investigators choose to use 0.10, 0.20 and 0.33 as prior toxicity distribution. CRM simulations indicate optimal performance of this design with high dose recommendation probabilities (at least 48%) and more patients allocated to the correct dose


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Pentamidine in Combination With Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Actual Study Start Date : December 19, 2018
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2030


Arm Intervention/treatment
Experimental: Pentamidine + ICE
Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
Drug: Pentamidine
Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) [ Time Frame: Up to 21 days ]
    Dose limiting toxicity (DLT) for hematological and non-hematological toxicities will be graded using National Cancer Institute (NCI) CTCAE Version 5.0


Secondary Outcome Measures :
  1. Determine Efficacy: best overall response [ Time Frame: Up to 112 days ]
    Individual best overall response at 5 and 16 weeks from enrollment, patients will be categorized as either a responder (complete response, partial response) versus nonresponders (stable disease, progressive disease).

  2. Define the Duration of Response [ Time Frame: Up to 112 days ]
    Duration of response as defined starting from the first occurrence of response until disease progression or death.

  3. Identify Immunohistochemistry Biomarkers [ Time Frame: Up to 112 days ]
    Immunohistochemistry staining of paraffin fixed tissue sample and peripheral blood will be done to assess the ability of pentamidine to inhibit its pharmacological target through PRL-3 expression.

  4. Polymerase Chair Reaction (PCR) analysis of Biomarkers [ Time Frame: Up to 112 days ]
    Digital PCR analysis of paraffin fixed tissue sample and peripheral blood will be done to assess PRL-3 expression and compare to the immunohistochemistry staining to determine the ideal testing modality for PRL-3 in cHL.

  5. Identify Phosphorylation Biomarkers [ Time Frame: Up to 112 days ]
    Pentamidine concentration/protein phosphorylation will be measured in PBMC and plasma samples collected throughout treatment.

  6. Identify sCD30 and TARC Biomarkers [ Time Frame: Up to 112 days ]
    Biomarkers: ELISA testing will be used to assess levels of sCD30 and TARC in serum samples collected prior to initiation of therapy and subsequent cycles.


Other Outcome Measures:
  1. Measure cfmRNA Biomarkers [ Time Frame: Up to 112 days ]
    Digital PCR analysis of the peripheral blood plasma will be used to measure cfmRNA during therapy

  2. Measure Circulating-free DNA (cfDNA) Biomarkers [ Time Frame: Up to 112 days ]
    digital PCR analysis of the peripheral blood plasma will be used to measure cfDNA during therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years old or older
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Subjects with histologically confirmed relapse or refractory cHL who had received a front-line anthracycline-containing regimen.
  • Subjects must have at least one measurable lesion >1.5cm as defined by the lymphoma response criteria.
  • Subjects must have recovered from their last prior chemotherapy; if they have received an investigational agent, at least 5 half-lives must have expired to assure clearance of prior therapy.
  • Prior radiation should have been completed at least 4 weeks prior to study Day 1.
  • Toxicities related to prior therapy must have returned to Grade 1 or less except for alopecia. Peripheral neuropathy must be grade 2 or less.
  • Adequate bone marrow function defined as: 1) Absolute neutrophil count ≥ 1000/µl and 2) Platelet count ≥ 50,000/µl
  • Adequate organ function: 1) Creatinine Clearance (CrCl) >60 mL/min and 2) Aspartate Aminotransferase (AST) ≤ 3 upper limit normal (ULN), and Alanine Aminotransferase (ALT) ≤3 ULN, and Bilirubin ≤ 1.5 ULN (Unless they have Gillbert's disease)
  • Ability to comply with the treatment, evaluations and required study follow-up.

Exclusion Criteria:

  • Subjects with central nervous system involvement.
  • Subjects with concomitant second malignancy (except adequately treated non-melanoma skin cancer, ductal carcinoma in-situ, superficial bladder cancer, prostate cancer or in situ cervical cancer) are excluded unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated.
  • A serious uncontrolled medical disorder or active infection which impairs the ability of the subject to receive protocol therapy or whose control is jeopardized by the complication of this therapy.
  • Prior organ allograft or allogeneic bone marrow transplantation.
  • Positive for HIV (1/2) or known acquired immunodeficiency syndrome.
  • Positive for hepatitis B Surface Ag, or antibody to hepatitis B core ag, or hepatitis C antibody or hepatitis C RNA in serum.
  • Ejection fraction less than 45% in subjects with prior anthracycline therapy (measurement of ejection fraction is mandatory).
  • Corrected QT interval (QTc) prolongation of more than 500.
  • Women of reproductive age who are unwilling or unable to use an acceptable method to minimize the risk of pregnancy for the entire study period and for at least 18 weeks after the last dose of pentamidine.
  • Women who are pregnant or breast-feeding.
  • Women with a positive pregnancy test (serum assay) on enrollment or prior to pentamidine administration.
  • Sexually active men not using birth control if their partners are women of reproductive age.
  • Prisoner or subjects who are involuntarily incarcerated.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pentamidine and/or ifosfamide, carboplatin and etoposide.
  • No investigational or commercial agents or therapies other than those specified by the protocol may be administered with the intent to treat the patient's malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03730363


Contacts
Layout table for location contacts
Contact: Jeri Reynolds 859-218-0131 jzreyn0@uky.edu
Contact: Heather Heath 859-323-6720 heather.flynn@uky.edu

Locations
Layout table for location information
United States, Kentucky
University of Kentucky Markey Cancer Center Recruiting
Lexington, Kentucky, United States, 40536
Contact: Jeri Reynolds         
Principal Investigator: Hayder Saeed, MD         
Sponsors and Collaborators
University of Kentucky
Investigators
Layout table for investigator information
Principal Investigator: Hayder Saeed, MD Lucille P. Markey Cancer Center at University of Kentucky

Layout table for additonal information
Responsible Party: Hayder Saeed, Principal Investigator, University of Kentucky
ClinicalTrials.gov Identifier: NCT03730363     History of Changes
Other Study ID Numbers: MCC-18-HEM-13
First Posted: November 5, 2018    Key Record Dates
Last Update Posted: December 20, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Hayder Saeed, University of Kentucky:
Pentamidine
Salvage Chemotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pentamidine
Antifungal Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Trypanocidal Agents